Poolbeg Pharma (LON:POLB) Shares Up 5.2% – Should You Buy?

Shares of Poolbeg Pharma PLC (LON:POLB) rose 5.2% during trading on Wednesday . The stock traded as high as GBX 8.10 ($0.11) and last traded at GBX 8.10 ($0.11). Approximately 475,472 shares traded hands during trading, a decline of 73% from the average daily volume of 1,772,456 shares. The stock had previously closed at GBX 7.70 ($0.10).

Poolbeg Pharma Stock Up 5.2 %

The stock’s 50 day simple moving average is GBX 9.65 and its two-hundred day simple moving average is GBX 11.64. The company has a market cap of £42.06 million, a PE ratio of -841.20 and a beta of 2.11.

About Poolbeg Pharma

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.